Clinical Trial Update: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the addition of Herceptin Hylecta or Phesgo to standard chemotherapy for HER2-positive endometrial serous carcinoma or ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinosarcoma
• Endometrial Serous Carcinoma

Drugs mentioned

• HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK)
• PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 3 | Status: RECRUITING